<DOC>
	<DOC>NCT01468181</DOC>
	<brief_summary>This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).</brief_summary>
	<brief_title>A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Participants who have had a diagnosis of type 2 diabetes mellitus before screening Participants who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), BG, TZD, aGI or glinides monotherapy for at least 3 months before screening and have been on a stable dose for at least 8 weeks before screening Participants must have a qualifying HbA1c value of 7.0% to 11.0% at screening Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m^2) Participants who have a diagnosis of type 1 diabetes Participants who have previously been treated with any other glucagonlike peptide1 (GLP1) analog within the 3 months before screening Participants who are currently taking insulin or have had previous insulin treatment within the 3 months before screening Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening Participants who have self or family history of medullary Ccell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Oral antihyperglycemic medications</keyword>
	<keyword>Long-Term Safety</keyword>
	<keyword>GLP 1</keyword>
	<keyword>Glucagon like peptide 1</keyword>
</DOC>